Adjuvant therapy with high dose vitamin D following primary treatment of melanoma at high risk of recurrence: a placebo controlled randomised phase II trial (ANZMTG 02.09 Mel-D)

Table 1 TNM classification for CM (3)

Classification	Thickness (mm)		Ulceration status/Mitoses
Tis	N/A	a	N/A
T1	N/A	a	Without ulceration and mitosis <1/mm²
		b	With ulceration or mitosis ≥1/mm²
T2	1.01-2.00	a	Without ulceration
		b	With ulceration
T3	2.01-4.00	a	Without ulceration
		b	With ulceration
T4	>4.00	a	Without ulceration
		b	With ulceration
N	No. metastatic nodes		Nodal metastatic burden
N0	0	a	N/A
N1	1 node involved		Micrometastases*
	1 node involved	b	Macrometastases†
N2	2-3 nodes involved	a	Micrometastases
	2-3 nodes involved	b	Macrometastases
		c	Intransit metastases/ satellites without metastatic nodes
N3	4+ metastatic nodes or matted nodes or intransit metastases/satellites with metastatic nodes
M	Site		Serum LDH
M0	No distant metastases		N/A
M1a	Distant skin, subcutaneous or nodal metastases		Normal
M1b	Lung metastases		Normal
M1c	All other visceral metastases		Normal
M1c	Any distant metastasis		Elevated

*Micrometastases are diagnosed after sentinel lymph node biopsy.
†Macrometastases are defined as clinically detectable nodal metastases confirmed pathologically.

ISSN: 1471-2407